Effect of celecoxib, a cyclooxygenase-2-specific inhibitor, on insulin sensitivity, C-reactive protein, homocysteine, and metabolic profile in overweight or obese subjects

Metabolic Syndrome and Related Disorders

Volumn 3, Issue 2, 2005, Pages 95-101

  González Ortiz, Manuel ^a,b   Pascoe González, Sara ^a   Martínez Abundis, Esperanza ^a   Kam Ramos, Angélica M ^a   Hernández Salazar, Eduardo ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b NONE   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; HOMOCYSTEINE; INSULIN; PLACEBO;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HYPERINSULINEMIA; INFLAMMATORY DISEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; METABOLIC PARAMETERS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VASCULAR DISEASE; VOLUNTEER;

EID: 24644475268     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2005.3.95     Document Type: Article

References (24)

1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
2. Lorenzo C, Okoloise M, Williams K, et al. The metabolic syndrome as predictor of type 2 diabetes. Diabetes Care 2003;26:3153-3159.
3. Moller DE, Berger JP. Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes 2003;27:S17-S21.
4. Sowers JR, Frohlich ED. Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. Med Clin North Am 2004;88:63-82.
5. Matthaei S, Stumvoll M, Kellerer M, et al. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 2000;21:585-618.
6. Senn JJ, Mover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3): a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746.
7. Han TS, Sattar N, Williams K, et al. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002;25: 2016-2021.
8. Meigs JB, Jacques PF, Selhub J, et al. Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham offspring study. Diabetes Care 2001;24:1403-1410.
9. Brune K, Hinz B. Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 2004;33:1-6.
10. González-Ortiz M, Martínez-Abundis BR, Balcázar-Muñoz JA, et al. Inhibition of cyclooxygenase-1 or 2 on insulin sensitivity in healthy subjects. Horm Metab Res 2001;33:250-253.
11. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
12. Jeyaseelan L, Rao PSS. Methods of determining sample sizes in clinical trials. Indian Pediatr 1989;26:115-121.
13. Gum RJ, Gaede LL, Koterski SL, et al. Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice. Diabetes 2003;52: 21-28.
14. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes 2003;27:S6-S11.
15. Marette A. Molecular mechanisms of inflammation in obesity-linked insulin resistance. Int J Obes 2003; 27:S46-S48.
16. Singh N, Morris K, Alan R, et al. Pioglitazone, but not the specific PPARγ agonist, GW7845, down regulated glycated protein induced cyclooxygenease 2 expression in human monocytes. Diabetes 2003; 52(suppl 1):A180.
17. 2 synthase, and inducible nitric oxide synthase in cardiac myocytes. Hypertension 2003;42:844-850.
18. Shanmugam N, Gaw Gonzalo IT, Natarajan R. Molecular mechanisms of high glucose-induced cyclooxygenase-2 expression in monocytes. Diabetes 2004; 53:795-802.
19. Chinetti G, Fruchart JC, Staels B. Peroxisome proliferators-activated receptors and inflammation: from basic science to clinical applications. Int J Obes 2003; 27:S41-S45.
20. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004;89:2728-2735.
21. Dandona P, Aljada A, Dhindsa S, et al. Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone 2003;Suppl 4:S13-S20.
22. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
23. Title LM, Giddens K, McInerney MM, et al. Effect of cyclooxygenase-2 inhibition with rofecoxib on endothelial dysfunction and inflammatory markers in patients with coronary artery disease. J Am Coll Cardiol 2003;42:1747-1753.
24. O'Grady H, Kelly C, Bouchier-Hayes D, et al. Homocysteine and occlusive arterial disease. Br J Surg 2002;89:838-844.